Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer

Archive ouverte

Källberg, Julia | Harrison, Alexandra | March, Valerie | Bērziņa, Santa | Nemazanyy, Ivan | Kepp, Oliver | Kroemer, Guido | Mouillet-Richard, Sophie | Laurent-Puig, Pierre | Taly, Valérie | Xiao, Wenjin

Edité par CCSD ; Nature Publishing Group -

International audience. The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy.

Suggestions

Du même auteur

Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside

Archive ouverte | Bērziņa, Santa | CCSD

International audience. Tumor-on-chip technology has cemented its importance as an in vitro tumor model for cancer research. Its ability to recapitulate different elements of the in vivo tumor microenvironment makes...

Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype

Archive ouverte | Deng, Jiayin | CCSD

International audience. Abstract Colorectal cancers (CRC) can be classified into four consensus molecular subtypes (CMS), among which CMS1 has the best prognosis, contrasting with CMS4 that has the worst outcome. CM...

Frontiers in single cell analysis: multimodal technologies and their clinical perspectives

Archive ouverte | Källberg, Julia | CCSD

International audience. Single cell multimodal analysis is at the frontier of single cell research: it defines the roles and functions of distinct cell types through simultaneous analysis to provide unprecedented in...

Chargement des enrichissements...